Final Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented at 2023 ASDS Annual Meeting

Rhea-AI Summary

Evolus to present final results from Phase 2 study at 2023 ASDS Annual Meeting

Positive

• Evolus to present final results from Phase 2 study on 40U PrabotulinumtoxinA-xvfs at ASDS Annual Meeting
• Study evaluates safety, efficacy, and duration of effect in Glabellar Lines
• Presentation by Sue Ellen Cox M.D.
• Independent medical education session

Negative

• None.

• Oral abstract will be presented on Friday, November 3, 2023

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Sue Ellen Cox M.D. will present final results from the Phase 2 study evaluating the safety, efficacy and duration of effect of 40U PrabotulinumtoxinA-xvfs at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting on November 3, 2023, in Chicago during an independent medical education session.

Oral Presentation Information

Title: A Phase II, Randomized, Double Blind, Active-Controlled, Increasing Dose Trial to Study the Safety and Duration of Effect of 40U PrabotulinumtoxinA-xvfs in Glabellar Lines: Final Results
Time: 4:30 to 5:30 pm CT, Friday, November 3, 2023

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), globally licensed under the brand name Nuceiva®. The product is manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, a line of five unique dermal fillers currently in late-stage development. Visit us at www.evolus.com, and follow us on LinkedIn, Twitter, Instagram or Facebook.

Jeuveau^® and Nuceiva^® are registered trademarks of Evolus, Inc.
Hi-Pure^™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231024386212/en/

Investor Contact:

Idalia Rodriguez, Ned Mitchell

Arbor Advisory Group

Email: ir@evolus.com

Media Contact:

Email: media@evolus.com

Source: Evolus

FAQ

What is the focus of Evolus, Inc.?

Evolus is a performance beauty company with a focus on building an aesthetic portfolio of consumer brands.

What will be presented at the 2023 ASDS Annual Meeting?

Final results from the Phase 2 study on 40U PrabotulinumtoxinA-xvfs in Glabellar Lines.

Who will be presenting the results?

Sue Ellen Cox M.D.

When and where will the presentation take place?

The presentation will take place on November 3, 2023, at the ASDS Annual Meeting in Chicago during an independent medical education session.

What does the study evaluate?

The study evaluates the safety, efficacy, and duration of effect of 40U PrabotulinumtoxinA-xvfs in Glabellar Lines.